Stockreport

Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs

Iovance Biotherapeutics, Inc.  (IOVA) 
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com
PDF Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileu [Read more]